Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2208746
Abstract: ABSTRACT Introduction There are no drugs approved by regulatory agencies for the treatment of nonalcoholic fatty liver disease (NAFLD); incretin combination therapies are being developed for treatment of type 2 diabetes and research has moved… read more here.
Keywords: combination therapies; incretin combination; combination; looking ahead ... See more keywords